AZD-7268 is a δ-opioid receptor agonist which was under development for the treatment of major depressive disorder but was never marketed.[1][2][3] It is taken by mouth.[1]
 | |
| Clinical data | |
|---|---|
| Other names | AZD7268; AZ12488024; AZ-12488024 |
| Routes of administration | Oral[1] |
| Drug class | δ-Opioid receptor agonist[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| ECHA InfoCard | 100.205.777 |
| Chemical and physical data | |
| Formula | C29H30N4O2S |
| Molar mass | 498.65 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The affinity (Ki) of AZD-7268 for the δ-opioid receptor was reported to be 2.7 nM and its selectivity for this receptor over the μ-opioid receptor was reported to be 2,000-fold.[4] No animal studies of AZD-7268 appear to have been published.[3][4] In addition to putative antidepressant effects, AZD-7268 might have anxiolytic effects.[4][3] Structurally, AZD-7268 was derived from SNC-80.[4]
Dose-limiting side effects of AZD-7268 in clinical trials included syncope (fainting), hypotension (low blood pressure), and dizziness.[3]
AZD-7268 was first described by 2007.[3] Its development was discontinued in 2010.[3][1] It reached phase 2 clinical trials prior to the discontinuation of its development.[1] No reason was given for the discontinuation of its development.[3] However, the drug was found to be ineffective for major depressive disorder in a phase 2 clinical trial of 231 participants comparing it with placebo and escitalopram.[3][5][4][6] The drug was under development by AstraZeneca.[1]
See also
editReferences
edit- ^ a b c d e f g "AZD 7268". AdisInsight. 5 November 2023. Retrieved 22 October 2024.
- ^ "Delving into the Latest Updates on AZD-7268 with Synapse". Synapse. 19 September 2024. Retrieved 22 October 2024.
- ^ a b c d e f g h Mandrioli R, Mercolini L (April 2015). "Discontinued anxiolytic drugs (2009 - 2014)". Expert Opin Investig Drugs. 24 (4): 557–573. doi:10.1517/13543784.2014.998335. PMID 25557457.
- ^ a b c d e Fujii H, Takahashi T, Nagase H (September 2013). "Non-peptidic δ opioid receptor agonists and antagonists (2000 - 2012)". Expert Opin Ther Pat. 23 (9): 1181–1208. doi:10.1517/13543776.2013.804066. PMID 23705966.
- ^ Sakurai H, Yonezawa K, Tani H, Mimura M, Bauer M, Uchida H (July 2022). "Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry". Pharmacopsychiatry. 55 (4): 193–202. doi:10.1055/a-1714-9097. PMC 9259184. PMID 35045580.
- ^ Connolly KR, Thase ME (March 2012). "Emerging drugs for major depressive disorder". Expert Opin Emerg Drugs. 17 (1): 105–126. doi:10.1517/14728214.2012.660146. PMID 22339643.
 | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |